Drug Trial Radar · NCT03824392
Study of Intravenous ATYR1923 (Efzofitimod) for Pulmonary Sarcoidosis
Last checked: Nov 19, 2026Latest source record: Jul 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
37
Actual
Start
Jan 29, 2019
Primary completion
Jun 29, 2021
Study completion Jun 29, 2021
Sponsor
- Lead sponsor
- aTyr Pharma, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Foundation for Sarcoidosis Research
- First posted
- Jan 31, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized, double-blind, placebo matched to efzofitimod-controlled, study will evaluate the safety, tolerability, immunogenicity, pharmacokinetic (PK), and preliminary efficacy of multiple ascending doses of IV efzofitimod in participants with pulmonary sarcoidosis undergoing a protocol-guided oral corticosteroid (OCS) tapering regimen.This study will consist of 3 staggered multiple dose cohorts. Each eligible participant will participate in only one cohort during the study. Within each cohort, 12 participants will be randomized 2:1 to efzofitimod (N=8) or placebo matched to efzofitimod (N=4).
Conditions
- Pulmonary Sarcoidosis
Interventions
Efzofitimod 1.0 mg/kg or PlaceboBiological
Participants to receive efzofitimod 1.0 mg/kg IV every 4 weeks or placebo matched to efzofitimod every 4 weeks
Efzofitimod 3.0 mg/kg or PlaceboBiological
Participants to receive efzofitimod 3.0 mg/kg IV every 4 weeks or placebo matched to efzofitimod every 4 weeks
Efzofitimod 5.0 mg/kg or PlaceboBiological
Participants to receive efzofitimod 5.0 mg/kg IV every 4 weeks or placebo matched to efzofitimod every 4 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Time frame: Baseline up to Week 24
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama
Birmingham, Alabama
aTyr Investigative Site
Northridge, California
National Jewish Health
Denver, Colorado
aTyr Investigative Site
Miami, Florida
Emory University
Atlanta, Georgia
Northwestern University
Chicago, Illinois
aTyr Investigative Site
Chicago, Illinois
University of Iowa
Iowa City, Iowa
University of Louisville
Louisville, Kentucky
East Carolina University
Greenville, North Carolina
University of Cincinnati
Cincinnati, Ohio
Cleveland Clinic
Cleveland, Ohio
Medical University of South Carolina
Charleston, South Carolina
UT Southwestern Medical Center
Dallas, Texas
Inova Fairfax Medical Center
Falls Church, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.